(redirected from Cardiac Allograft Vasculopathy)
Category filter:
CAVComputer-Aided Verification
CAVConstant Angular Velocity
CAVComposite Audio Video
CAVComputer Aided Verification
CAVConcept Activity Vehicle
CAVConstant Air Volume
CAVCampus Andaluz Virtual (Spanish virtual campus)
CAVCanine Adenovirus
CAVCentre d'Art Visuel (French: Visual Art Center; France and Switzerland)
CAVContrat d'Avenir (French: Future Contract; employment contract)
CAVCommon Aero Vehicle
CAVCardiac Allograft Vasculopathy
CAVChicken Anemia Virus
CAVComputer Audio Video (music system)
CAVCollision Avoidance System
CAVCyclophosphamide Doxorubicin Vincristine
CAVCoalition Anti-Vivisection (Belgium)
CAVCommercial Asset Visibility
CAVCentre Alexis Vautrin (French: Alexis Vautrin Center; est. 1924; Vandoeuvre-les-Nancy, France)
CAVAviation Heavy Cruiser
CAVComposite Armored Vehicle
CAVCumulative Absolute Velocity (seismology)
CAVConfrérie des Amateurs de Vapeur (French: Brotherhood of Steam Enthusiasts)
CAVComponent Averaging (numerical technique for solving large sparse linear systems)
CAVColegio de Arquitectos de Venezuela (Spanish: Venezuela Association of Architects)
CAVCommon Aerospace Vehicle
CAVCentro Ecuménico Antonio Valdivieso (Antonio Valdivieso Ecumenical Centre)
CAVCommand Assistance Visit (US DoD)
CAVComputer Assisted Valuation (real property)
CAVCentral Africa Vision
CAVCompound Accreted Value
CAVCampo de Visão (Portugese)
CAVChick Anemia Virus
CAVCorrective Action Verification
CAVCentre Astronomique Vendéen (French: Vendéen Astronomical Center; Vendée, France)
CAVClub d'Aviron Vésenaz (French: Rowing Club Vésenaz; Vésenaz, Switzerland)
CAVCommand Assault Vehicle
CAVCrack Arrest Verification
CAVCombat Autonomous Vehicle
CAVClub Automodélisme de Viglain (French: Auto-Modeler Club of Viglain; Viglain, France)
CAVCommand Authority Violation
CAVConsolidated Adjustment Voucher
CAVContrat Assurance Vie (French: Life Insurance Contract)
CAVChampagne Audiovisuel (French: Champagne Audiovisual; Cormontreuil, France)
CAVComputer Aided Vexillology
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Weis, "Cardiac allograft vasculopathy recent developments," Circulation, vol.
In conclusion, the data of this study indicate that the feature most characteristically associated to cardiac allograft vasculopathy, namely vessel stenosis, was strongly ameliorated by the LDE-MTX treatment, along with the grade of necrosis and markers of the inflammatory process.
Starling et al., "Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the everolimus versus mycophenolate mofetil randomized, multicenter trial," JACC: Heart Failure, vol.
Basha et al., "Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation," Human Immunology, vol.
* Prevention for cardiac allograft vasculopathy including monitoring of cardiovascular risk factors including hypertension, diabetes, hyperlipidemia, smoking and obesity.
The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 2006;25:420-5.
Cardiac allograft vasculopathy (CAV) is common after successful heart transplantation; the prevalence of angiographically detectable CAV at one, three and five years after transplantation in cyclosporine treated patients is 14%, 37% and 50% respectively (1).
An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol 1995; 75: 853-4.
Rouvier et al., "Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection," American Journal of Transplantation, vol.
This revised definition of BNR has been noted to result in a decrease in 3-year subsequent survival, lower subsequent freedom from cardiac allograft vasculopathy (CAV), and a decrease in freedom from nonfatal major adverse cardiac events (NF-MACE) [13].
Research on chronic rejection in heart and lung transplantation will be a primary focus, including cardiac allograft vasculopathy and reperfusion injury in heart and lung transplantation.